• X Bonfill, C Serra, M Sacristán, M Nogué, F Losa, and J Montesinos.
• Centro Cochrane Iberoamericano., Hospital de la Santa Creu i Sant Pau, Sant Antoni M. Claret 171, Barcelona, Catalonia, Spain, 08041. XBonfill@hsp.santpau.es
• Cochrane Db Syst Rev. 2001 Jan 1; 2002 (4): CD002804CD002804.

BackgroundThe role of second-line chemotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) who have relapsed or failed to respond to first-line treatment was unclear.ObjectivesTo determine the effectiveness of any second-line chemotherapy in patients with NSCLC.Search StrategyBibliographic databases were searched. Handsearching and contact with experts was also performed.Selection CriteriaRandomised controlled clinical trials in which any second-line chemotherapy was compared with BSC in patients with NSCLC who had previously failed to any previous chemotherapy regimen.Data Collection And AnalysisData was extracted by 2 independent reviewers and revised by all authors.Main ResultsOnly one study was included. It randomised 204 patients to receive either doxetaxel or BSC. Following an unacceptably high toxic death rate the dose of doxetaxel was reduced from 100 mg/m(2) to 75 mg/m(2). Doxetaxel gave an extra 2.4 months of survival - an average of 7.0 months vs 4.6 months on BSC. At 1 year after diagnosis 29% of doxetaxel treated patients were alive compared with 19% of the BSC group.Reviewer's ConclusionsDefinitive recommendations cannot be made since evidence is only available from one randomised controlled trial which, though of reasonable quality, had a number of limitations. There is currently no evidence to support second-line treatment of patients with poor performance status. Larger, well-designed controlled trials are needed to further evaluate whether the benefits of second-line chemotherapy to patients with NSCLC outweigh its risks and costs.

16 keywords...

hide…